Related Experiment Video

Updated: Jan 4, 2026

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.3K

Prediction of Drug-Resistant Epilepsy in Children With Cerebral Palsy

Itay Tokatly Latzer1,2, Amit Blumovich1,2, Liora Sagi1,2

  • 1Pediatric Neurology Institute, The Dana-Dwek Children's Hospital, Tel Aviv Medical Center, Tel Aviv, Israel.

Journal of Child Neurology
|November 6, 2019
PubMed

Insights

Identifying risk factors for drug-resistant epilepsy in children with cerebral palsy is crucial. A predictive model using Apgar score, neonatal seizures, focal epilepsy, and EEG findings can aid early prediction for better seizure control.

Area of Science:

  • Neurology
  • Pediatrics
  • Clinical Medicine

Background:

  • Epilepsy affects approximately 40% of individuals with cerebral palsy.
  • Characteristics defining drug-resistant epilepsy in this population are not well understood.

Purpose of the Study:

  • To identify clinical risk factors predicting drug-resistant epilepsy in children with cerebral palsy.
  • To develop a simple predictive model for clinical application.

Main Methods:

  • Retrospective chart review of 118 children with cerebral palsy (2013-2018).
  • Analysis of clinical parameters in patients with drug-resistant versus controlled epilepsy.

Main Results:

  • A predictive model for drug-resistant epilepsy was established.
  • Key predictors include low Apgar score (5 minutes), neonatal seizures, focal-onset epilepsy, and focal slowing on electroencephalogram (EEG).
  • The model achieved an area under the receiver operating characteristic of 0.840.

Conclusions:

  • A simple predictive model for drug-resistant epilepsy in children with cerebral palsy has been developed.
  • Early identification of children at risk can facilitate timely interventions for improved seizure management.

Keywords:
cerebral palsychildrendrug-resistantepilepsyintractableseizures

More Related Videos

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.4K
Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

21.0K

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
772
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
844
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.3K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
160